Access this chapter
Tax calculation will be finalised at checkout
Purchases are for personal use only
Abbreviations
- AASLD:
-
American Association for the Study of Liver Diseases
- AH:
-
Alcoholic hepatitis
- ATP:
-
Adenosine triphosphate
- CDC:
-
Center for disease control
- CTP:
-
Child-Turcotte-Pugh
- ECM:
-
Extracellular matrix
- HBV:
-
Hepatitis B virus
- HCC:
-
Hepatocellular carcinoma
- HCV:
-
Hepatitis C virus
- HPS:
-
Hepatopulmonary syndrome
- HRS:
-
Hepatorenal syndrome
- HSC:
-
Hepatic stellate cell
- HVPG:
-
Hepatic venous pressure gradient
- IL:
-
Interleukin
- MDF:
-
Maddrey discriminant function
- MELD:
-
Model for end-stage liver disease
- NAFLD:
-
Nonalcoholic fatty liver disease
- NASH:
-
Nonalcoholic steatohepatitis
- POPH:
-
Portopulmonary hypertension
- PSE:
-
Portosystemic encephalopathy
- PVT:
-
Portal venous thrombosis
- SAAG:
-
Serum-ascites albumin gradient
- SBP:
-
Spontaneous bacterial peritonitis
- TGF:
-
Transforming growth factor
- TIPS:
-
Transjugular intrahepatic portosystemic shunt
- TLRs:
-
Toll-like receptors
- TNF:
-
Tumor necrosis factor
- USPSTF:
-
United States preventative services task force
References
Heron M. Deaths: Leading Causes for 2014. Natl Vital Stat Rep. 2016;65:1–96.
Scaglione S, et al. The epidemiology of cirrhosis in the United States: a population-based study. J Clin Gastroenterol. 2015;49(8):690–6.
Graudal N, et al. Characteristics of cirrhosis undiagnosed during life: a comparative analysis of 73 undiagnosed cases and 149 diagnosed cases of cirrhosis, detected in 4929 consecutive autopsies. J Intern Med. 1991;230(2):165–71.
Giarelli L, et al. Occurrence of liver cirrhosis among autopsies in Trieste. IARC Sci Publ. 1991;112:37–43.
Mokdad AH, et al. The continuing epidemics of obesity and diabetes in the United States. JAMA. 2001;286(10):1195–200.
Hsu CC, et al. Poverty increases type 2 diabetes incidence and inequality of care despite universal health coverage. Diabetes Care. 2012;35(11):2286–92.
Denniston MM, et al. Chronic hepatitis C virus infection in the United States, National Health and Nutrition Examination Survey 2003 to 2010. Ann Intern Med. 2014;160(5):293–300.
Mellinger JL, et al. Variation among United States hospitals in inpatient mortality for cirrhosis. Clin Gastroenterol Hepatol. 2015;13(3):577–84. quiz e30
Younossi ZM, et al. Changes in the prevalence of the most common causes of chronic liver diseases in the United States from 1988 to 2008. Clin Gastroenterol Hepatol. 2011;9(6):524–530.e1. quiz e60
Wong RJ, et al. Nonalcoholic steatohepatitis is the second leading etiology of liver disease among adults awaiting liver transplantation in the United States. Gastroenterology. 2015;148(3):547–55.
Chalasani N, et al. The diagnosis and management of non-alcoholic fatty liver disease: practice Guideline by the American Association for the Study of Liver Diseases, American College of Gastroenterology, and the American Gastroenterological Association. Hepatology. 2012;55(6):2005–23.
Williams CD, et al. Prevalence of nonalcoholic fatty liver disease and nonalcoholic steatohepatitis among a largely middle-aged population utilizing ultrasound and liver biopsy: a prospective study. Gastroenterology. 2011;140(1):124–31.
Bellentani S, et al. Epidemiology of non-alcoholic fatty liver disease. Dig Dis. 2010;28(1):155–61.
Calzadilla Bertot L, Adams LA. The natural course of non-alcoholic fatty liver disease. Int J Mol Sci. 2016;17(5). https://doi.org/10.3390/ijms17050774.
Goh GB, McCullough AJ. Natural history of nonalcoholic fatty liver disease. Dig Dis Sci. 2016;61(5):1226–33.
O’Shea RS, Dasarathy S, McCullough AJ. Alcoholic liver disease. Hepatology. 2010;51(1):307–28.
Teli MR, et al. Determinants of progression to cirrhosis or fibrosis in pure alcoholic fatty liver. Lancet. 1995;346(8981):987–90.
Leevy CM. Fatty liver: a study of 270 patients with biopsy proven fatty liver and review of the literature. Medicine. 1962;41:249–76.
Sorensen TI, et al. Prospective evaluation of alcohol abuse and alcoholic liver injury in men as predictors of development of cirrhosis. Lancet. 1984;2(8397):241–4.
Lok AS, McMahon BJ. Chronic hepatitis B: update 2009. Hepatology. 2009;50(3):661–2.
Blum HE. History and global burden of viral hepatitis. Dig Dis. 2016;34(4):293–302.
Chan SL, et al. Infection and cancer: the case of hepatitis B. J Clin Oncol. 2016;34(1):83–90.
Lavanchy D, Mark K. Global epidemiology of hepatitis B virus infection. In: Liaw Y-F, Zoulim F, editors. Hepatitis B virus in human diseases. Cham: Springer International Publishing; 2016.
Ott JJ, et al. Global epidemiology of hepatitis B virus infection: new estimates of age-specific HBsAg seroprevalence and endemicity. Vaccine. 2012;30(12):2212–9.
Wasley A, et al. The prevalence of hepatitis B virus infection in the United States in the era of vaccination. J Infect Dis. 2010;202(2):192–201.
McMahon BJ. Chronic hepatitis B virus infection. Med Clin North Am. 2014;98(1):39–54.
Hyams KC. Risks of chronicity following acute hepatitis B virus infection: a review. Clin Infect Dis. 1995;20(4):992–1000.
Benlloch S, Berenguer M. Chronic viral hepatitis. Friedman SL, Keeffe EB, Dienstag JL, editors. Philadelphia: Elselvier Saunders; 2012.
Fattovich G, Bortolotti F, Donato F. Natural history of chronic hepatitis B: special emphasis on disease progression and prognostic factors. J Hepatol. 2008;48(2):335–52.
Yang HI, et al. Hepatitis B e antigen and the risk of hepatocellular carcinoma. N Engl J Med. 2002;347(3):168–74.
Chen CJ, Yang HI, Iloeje UH. Hepatitis B virus DNA levels and outcomes in chronic hepatitis B. Hepatology. 2009;49(5 Suppl):S72–84.
Chen JD, et al. Carriers of inactive hepatitis B virus are still at risk for hepatocellular carcinoma and liver-related death. Gastroenterology. 2010;138(5):1747–54.
El-Serag HB. Epidemiology of viral hepatitis and hepatocellular carcinoma. Gastroenterology. 2012;142(6):1264–1273.e1.
Terrault NA, et al. AASLD guidelines for treatment of chronic hepatitis B. Hepatology. 2016;63(1):261–83.
Ditah I, et al. The changing epidemiology of hepatitis C virus infection in the United States: National Health and Nutrition Examination Survey 2001 through 2010. J Hepatol. 2014;60(4):691–8.
Alter MJ. Epidemiology of hepatitis C virus infection. World J Gastroenterol. 2007;13(17):2436–41.
Seeff LB. Natural history of chronic hepatitis C. Hepatology. 2002;36(5 Suppl 1):S35–46.
Centers for Disease Control and Prevention. Recommendations for prevention and control of hepatitis C virus (HCV) infection and HCV-related chronic disease. MMWR Recomm Rep. 1998;47(RR-19):1–39.
Moyer VA. Screening for hepatitis C virus infection in adults: U.S. Preventive Services Task Force recommendation statement. Ann Intern Med. 2013;159(5):349–57.
Surveillance for Viral Hepatitis – United States, 2014. http://www.cdc.gov/hepatitis/statistics/2014surveillance/index.htm. Accessed 18 Aug 2016
Malhi H, Gores GJ. Mechanisms of liver injury. In: Schiff ER, Maddrey WC, Sorrell MF, editors. Schiff’s diseases of the liver. 11th ed. Chichester: John Wiley and Sons; 2012. p. 216–31.
Lemasters JJ. V. Necrapoptosis and the mitochondrial permeability transition: shared pathways to necrosis and apoptosis. Am J Phys. 1999;276(1 Pt 1):G1–6.
Lemasters JJ. Dying a thousand deaths: redundant pathways from different organelles to apoptosis and necrosis. Gastroenterology. 2005;129(1):351–60.
Malhi H, Gores GJ, Lemasters JJ. Apoptosis and necrosis in the liver: a tale of two deaths? Hepatology. 2006;43(2 Suppl 1):S31–44.
Faouzi S, et al. Anti-Fas induces hepatic chemokines and promotes inflammation by an NF-kappa B-independent, caspase-3-dependent pathway. J Biol Chem. 2001;276(52):49077–82.
Jaeschke H, Lemasters JJ. Apoptosis versus oncotic necrosis in hepatic ischemia/reperfusion injury. Gastroenterology. 2003;125(4):1246–57.
Ogasawara J, et al. Lethal effect of the anti-Fas antibody in mice. Nature. 1993;364(6440):806–9.
Matsumura H, et al. Necrotic death pathway in Fas receptor signaling. J Cell Biol. 2000;151(6):1247–56.
Trautwein C, et al. Hepatic fibrosis: concept to treatment. J Hepatol. 2015;62(1 Suppl):S15–24.
Bataller R, Brenner DA. Liver fibrosis. J Clin Invest. 2005;115(2):209–18.
Lee YA, Wallace MC, Friedman SL. Pathobiology of liver fibrosis: a translational success story. Gut. 2015;64(5):830–41.
Iwaisako K, et al. Origin of myofibroblasts in the fibrotic liver in mice. Proc Natl Acad Sci U S A. 2014;111(32):E3297–305.
Lemoinne S, et al. Origins and functions of liver myofibroblasts. Biochim Biophys Acta. 2013;1832(7):|948–54.
Mederacke I, et al. Fate tracing reveals hepatic stellate cells as dominant contributors to liver fibrosis independent of its aetiology. Nat Commun. 2013;4:2823.
Friedman SL. Mechanisms of hepatic fibrogenesis. Gastroenterology. 2008;134(6):1655–69.
Jarnagin WR, et al. Expression of variant fibronectins in wound healing: cellular source and biological activity of the EIIIA segment in rat hepatic fibrogenesis. J Cell Biol. 1994;127(6 Pt 2):2037–48.
Friedman SL. Hepatic fibrosis: emerging therapies. Dig Dis. 2015;33(4):504–7.
Bosch J, et al. Hepatic endothelial dysfunction and abnormal angiogenesis: new targets in the treatment of portal hypertension. J Hepatol. 2010;53(3):558–67.
Kawada N, et al. The contraction of hepatic stellate (Ito) cells stimulated with vasoactive substances. Possible involvement of endothelin 1 and nitric oxide in the regulation of the sinusoidal tonus. Eur J Biochem. 1993;213(2):815–23.
Kaneda K, et al. Endothelin-1-induced vasoconstriction causes a significant increase in portal pressure of rat liver: localized constrictive effect on the distal segment of preterminal portal venules as revealed by light and electron microscopy and serial reconstruction. Hepatology. 1998;27(3):735–47.
Zhang JX, Pegoli W Jr, Clemens MG. Endothelin-1 induces direct constriction of hepatic sinusoids. Am J Phys. 1994;266(4 Pt 1):G624–32.
Gupta TK, et al. Endothelial dysfunction and decreased production of nitric oxide in the intrahepatic microcirculation of cirrhotic rats. Hepatology. 1998;28(4):926–31.
Tsochatzis EA, Bosch J, Burroughs AK. Liver cirrhosis. Lancet. 2014;383(9930):1749–61.
Giannini EG, Savarino V. Thrombocytopenia in liver disease. Curr Opin Hematol. 2008;15(5):473–80.
Garcia-Tsao G, et al. Prevention and management of gastroesophageal varices and variceal hemorrhage in cirrhosis. Hepatology. 2007;46(3):922–38.
Garcia-Tsao G, et al. Portal pressure, presence of gastroesophageal varices and variceal bleeding. Hepatology. 1985;5(3):419–24.
Abraldes JG, et al. Hemodynamic response to pharmacological treatment of portal hypertension and long-term prognosis of cirrhosis. Hepatology. 2003;37(4):902–8.
Runyon BA. Introduction to the revised American Association for the Study of Liver Diseases Practice Guideline management of adult patients with ascites due to cirrhosis 2012. Hepatology. 2013;57(4):1651–3.
Runyon BA. Ascites and spontaneous bacterial peritonitis. In: Feldman M, Friedman LS, Brandt LJ, editors. Sleisenger and Fordtran’s gastrointestinal and liver disease. 9th ed. Philadelphia: Saunder Elsevier; 2010.
Runyon BA. Management of adult patients with ascites due to cirrhosis: an update. Hepatology. 2009;49(6):2087–107.
Ge PS, Runyon BA. Treatment of patients with cirrhosis. N Engl J Med. 2016;375(8):767–77.
Planas R, et al. Natural history of patients hospitalized for management of cirrhotic ascites. Clin Gastroenterol Hepatol. 2006;4(11):1385–94.
D’Amico G, Garcia-Tsao G, Pagliaro L. Natural history and prognostic indicators of survival in cirrhosis: a systematic review of 118 studies. J Hepatol. 2006;44(1):217–31.
Runyon BA. Care of patients with ascites. N Engl J Med. 1994;330(5):337–42.
Gines P, et al. Management of cirrhosis and ascites. N Engl J Med. 2004;350(16):1646–54.
Such J, Runyon BA. Spontaneous bacterial peritonitis. Clin Infect Dis. 1998;27(4):669–74. quiz 675–6
Hung TH, Tsai CC, Hsieh YH. The long-term mortality of spontaneous bacterial peritonitis in cirrhotic patients: a 3-year nationwide cohort study. Turk J Gastroenterol. 2015;26(2):159–62.
Follo A, et al. Renal impairment after spontaneous bacterial peritonitis in cirrhosis: incidence, clinical course, predictive factors and prognosis. Hepatology. 1994;20(6):1495–501.
Tito L, et al. Recurrence of spontaneous bacterial peritonitis in cirrhosis: frequency and predictive factors. Hepatology. 1988;8(1):27–31.
Strauss RM, Boyer TD. Hepatic hydrothorax. Semin Liver Dis. 1997;17(3):227–32.
Xiol X, et al. Spontaneous bacterial empyema in cirrhotic patients: a prospective study. Hepatology. 1996;23(4):719–23.
D’Amico G, et al. Hepatic vein pressure gradient reduction and prevention of variceal bleeding in cirrhosis: a systematic review. Gastroenterology. 2006;131(5):1611–24.
Bosch J, Garcia-Pagan JC. Prevention of variceal rebleeding. Lancet. 2003;361(9361):952–4.
Vilstrup H, et al. Hepatic encephalopathy in chronic liver disease: 2014 Practice Guideline by the American Association for the Study of Liver Diseases and the European Association for the Study of the Liver. Hepatology. 2014;60(2):715–35.
Saunders JB, et al. A 20-year prospective study of cirrhosis. Br Med J. 1981;282(6260):263–6.
Romero-Gomez M, et al. Subclinical hepatic encephalopathy predicts the development of overt hepatic encephalopathy. Am J Gastroenterol. 2001;96(9):2718–23.
Jepsen P, et al. Clinical course of alcoholic liver cirrhosis: a Danish population-based cohort study. Hepatology. 2010;51(5):1675–82.
Coltorti M, et al. Liver cirrhosis in Italy. A multicentre study on presenting modalities and the impact on health care resources. National Project on Liver Cirrhosis Group. Ital J Gastroenterol. 1991;23(1):42–8.
Bustamante J, et al. Prognostic significance of hepatic encephalopathy in patients with cirrhosis. J Hepatol. 1999;30(5):890–5.
Lockwood AH. Blood ammonia levels and hepatic encephalopathy. Metab Brain Dis. 2004;19(3–4):345–9.
Bass NM, et al. Rifaximin treatment in hepatic encephalopathy. N Engl J Med. 2010;362(12):1071–81.
Rodriguez-Roisin R, Krowka MJ. Hepatopulmonary syndrome—a liver-induced lung vascular disorder. N Engl J Med. 2008;358(22):2378–87.
Zhang XJ, et al. Intrapulmonary vascular dilatation and nitric oxide in hypoxemic rats with chronic bile duct ligation. J Hepatol. 2003;39(5):724–30.
Rodriguez-Roisin R, et al. Pulmonary-hepatic vascular disorders (PHD). Eur Respir J. 2004;24(5):861–80.
Corley DA, et al. Lack of efficacy of TIPS for hepatopulmonary syndrome. Gastroenterology. 1997;113(2):728–30.
Allgaier HP, et al. Hepato-pulmonary syndrome: successful treatment by transjugular intrahepatic portosystemic stent-shunt (TIPS). J Hepatol. 1995;23(1):102.
Lasch HM, et al. Use of transjugular intrahepatic portosystemic shunt as a bridge to liver transplantation in a patient with severe hepatopulmonary syndrome. Liver Transpl. 2001;7(2):147–9.
Riegler JL, et al. Transjugular intrahepatic portosystemic shunt improves oxygenation in hepatopulmonary syndrome. Gastroenterology. 1995;109(3):978–83.
Selim KM, et al. Transjugular intrahepatic portosystemic shunt: a successful treatment for hepatopulmonary syndrome. Am J Gastroenterol. 1998;93(3):455–8.
Siramolpiwat S. Transjugular intrahepatic portosystemic shunts and portal hypertension-related complications. World J Gastroenterol. 2014;20(45):16996–7010.
Krowka MJ. Hepatopulmonary syndrome: recent literature (1997 to 1999) and implications for liver transplantation. Liver Transpl. 2000;6(4 Suppl 1):S31–5.
Pascasio JM, et al. Prevalence and severity of hepatopulmonary syndrome and its influence on survival in cirrhotic patients evaluated for liver transplantation. Am J Transplant. 2014;14(6):1391–9.
Hoeper MM, Krowka MJ, Strassburg CP. Portopulmonary hypertension and hepatopulmonary syndrome. Lancet. 2004;363(9419):1461–8.
Surani SR, et al. Pulmonary complications of hepatic diseases. World J Gastroenterol. 2016;22(26):6008–15.
Kochar R, Nevah Rubin MI, Fallon MB. Pulmonary complications of cirrhosis. Curr Gastroenterol Rep. 2011;13(1):34–9.
Budhiraja R, Hassoun PM. Portopulmonary hypertension: a tale of two circulations. Chest. 2003;123(2):562–76.
Halank M, et al. Portopulmonary hypertension. J Gastroenterol. 2006;41(9):837–47.
Swanson KL, et al. Survival in portopulmonary hypertension: Mayo Clinic experience categorized by treatment subgroups. Am J Transplant. 2008;8(11):2445–53.
Salerno F, et al. Diagnosis, prevention and treatment of hepatorenal syndrome in cirrhosis. Gut. 2007;56(9):1310–8.
Fede G, et al. Renal failure and cirrhosis: a systematic review of mortality and prognosis. J Hepatol. 2012;56(4):810–8.
Angeli P, et al. Reversal of type 1 hepatorenal syndrome with the administration of midodrine and octreotide. Hepatology. 1999;29(6):1690–7.
Esrailian E, et al. Octreotide/Midodrine therapy significantly improves renal function and 30-day survival in patients with type 1 hepatorenal syndrome. Dig Dis Sci. 2007;52(3):742–8.
Alessandria C, et al. Noradrenalin vs terlipressin in patients with hepatorenal syndrome: a prospective, randomized, unblinded, pilot study. J Hepatol. 2007;47(4):499–505.
Ghosh S, et al. Noradrenaline vs terlipressin in the treatment of type 2 hepatorenal syndrome: a randomized pilot study. Liver Int. 2013;33(8):1187–93.
Nassar Junior AP, et al. Terlipressin versus norepinephrine in the treatment of hepatorenal syndrome: a systematic review and meta-analysis. PLoS One. 2014;9(9):e107466.
Singh V, et al. Noradrenaline vs. terlipressin in the treatment of hepatorenal syndrome: a randomized study. J Hepatol. 2012;56(6):1293–8.
Eason JD, et al. Proceedings of consensus conference on simultaneous liver kidney transplantation (SLK). Am J Transplant. 2008;8(11):2243–51.
Nazar A, et al. LEFT ventricular function assessed by echocardiography in cirrhosis: relationship to systemic hemodynamics and renal dysfunction. J Hepatol. 2013;58(1):51–7.
Karagiannakis DS, et al. Diastolic cardiac dysfunction is a predictor of dismal prognosis in patients with liver cirrhosis. Hepatol Int. 2014;8(4):588–94.
Ruiz-del-Arbol L, et al. Diastolic dysfunction is a predictor of poor outcomes in patients with cirrhosis, portal hypertension, and a normal creatinine. Hepatology. 2013;58(5):1732–41.
Cazzaniga M, et al. Diastolic dysfunction is associated with poor survival in patients with cirrhosis with transjugular intrahepatic portosystemic shunt. Gut. 2007;56(6):869–75.
Rabie RN, et al. The use of E/A ratio as a predictor of outcome in cirrhotic patients treated with transjugular intrahepatic portosystemic shunt. Am J Gastroenterol. 2009;104(10):2458–66.
Chen Y, et al. A detailed evaluation of cardiac function in cirrhotic patients and its alteration with or without liver transplantation. J Cardiol. 2016;67(2):140–6.
Mohamed R, et al. Effect of liver transplantation on QT interval prolongation and autonomic dysfunction in end-stage liver disease. Hepatology. 1996;23(5):1128–34.
Torregrosa M, et al. Cardiac alterations in cirrhosis: reversibility after liver transplantation. J Hepatol. 2005;42(1):68–74.
Tsochatzis EA, et al. Systematic review: portal vein thrombosis in cirrhosis. Aliment Pharmacol Ther. 2010;31(3):366–74.
Francoz C, et al. Splanchnic vein thrombosis in candidates for liver transplantation: usefulness of screening and anticoagulation. Gut. 2005;54(5):691–7.
Amitrano L, et al. Risk factors and clinical presentation of portal vein thrombosis in patients with liver cirrhosis. J Hepatol. 2004;40(5):736–41.
Amitrano L, et al. Inherited coagulation disorders in cirrhotic patients with portal vein thrombosis. Hepatology. 2000;31(2):345–8.
Nery F, et al. Causes and consequences of portal vein thrombosis in 1,243 patients with cirrhosis: results of a longitudinal study. Hepatology. 2015;61(2):660–7.
Zocco MA, et al. Thrombotic risk factors in patients with liver cirrhosis: correlation with MELD scoring system and portal vein thrombosis development. J Hepatol. 2009;51(4):682–9.
American Cancer Society. Cancer facts and figures 2016. Atlanta, GA: American Cancer Society; 2016.
El-Serag HB, Kanwal F. Epidemiology of hepatocellular carcinoma in the United States: where are we? Where do we go? Hepatology. 2014;60(5):1767–75.
Ferlay J, et al. Cancer incidence and mortality worldwide: sources, methods and major patterns in GLOBOCAN 2012. Int J Cancer. 2015;​136(5):E359–86.
N.A. A new prognostic system for hepatocellular carcinoma: a retrospective study of 435 patients: the Cancer of the Liver Italian Program (CLIP) investigators. Hepatology 1998;28(3):751–5.
Andersson KL, et al. Cost effectiveness of alternative surveillance strategies for hepatocellular carcinoma in patients with cirrhosis. Clin Gastroenterol Hepatol. 2008;6(12):1418–24.
Bruix J, Sherman M. Management of hepatocellular carcinoma: an update. Hepatology. 2011;53(3):1020–2.
Trojan J, Zangos S, Schnitzbauer AA. Diagnostics and treatment of hepatocellular carcinoma in 2016: standards and developments. Visc Med. 2016;32(2):116–20.
Adhoute X, et al. Usefulness of staging systems and prognostic scores for hepatocellular carcinoma treatments. World J Hepatol. 2016;8(17):703–15.
Bruix J, Reig M, Sherman M. Evidence-based diagnosis, staging, and treatment of patients with hepatocellular carcinoma. Gastroenterology. 2016;150(4):835–53.
Bhardwaj N, Perera MT, Silva MA. Current treatment approaches to HCC with a special consideration to transplantation. J Transplant. 2016;2016:7926264.
Ripoll C, et al. Hepatic venous pressure gradient predicts clinical decompensation in patients with compensated cirrhosis. Gastroenterology. 2007;133(2):481–8.
Child CG, Turcotte JG. Surgery and portal hypertension. Major Probl Clin Surg. 1964;1:1–85.
Cholongitas E, et al. Systematic review: the model for end-stage liver disease—should it replace Child-Pugh’s classification for assessing prognosis in cirrhosis? Aliment Pharmacol Ther. 2005;22(11–12):1079–89.
Martin P, et al. Evaluation for liver transplantation in adults: 2013 practice guideline by the American Association for the Study of Liver Diseases and the American Society of Transplantation. Hepatology. 2014;59(3):1144–65.
Malinchoc M, et al. A model to predict poor survival in patients undergoing transjugular intrahepatic portosystemic shunts. Hepatology. 2000;31(4):864–71.
Kamath PS, et al. A model to predict survival in patients with end-stage liver disease. Hepatology. 2001;33(2):464–70.
Wiesner RH, et al. MELD and PELD: application of survival models to liver allocation. Liver Transpl. 2001;7(7):567–80.
Wiesner R, et al. Model for end-stage liver disease (MELD) and allocation of donor livers. Gastroenterology. 2003;124(1):91–6.
Hwang JH, et al. The role of endoscopy in the management of variceal hemorrhage. Gastrointest Endosc. 2014;80(2):221–7.
Marcellin P, et al. Regression of cirrhosis during treatment with tenofovir disoproxil fumarate for chronic hepatitis B: a 5-year open-label follow-up study. Lancet. 2013;381(9865):468–75.
Xu B, et al. Long-term lamivudine treatment achieves regression of advanced liver fibrosis/cirrhosis in patients with chronic hepatitis B. J Gastroenterol Hepatol. 2015;30(2):372–8.
Buti M, et al. Long-term clinical outcomes in cirrhotic chronic hepatitis B patients treated with tenofovir disoproxil fumarate for up to 5 years. Hepatol Int. 2015;9(2):243–50.
D’Ambrosio R, et al. A morphometric and immunohistochemical study to assess the benefit of a sustained virological response in hepatitis C virus patients with cirrhosis. Hepatology. 2012;56(2):532–43.
Hezode C, et al. Liver stiffness diminishes with antiviral response in chronic hepatitis C. Aliment Pharmacol Ther. 2011;34(6):656–63.
Falize L, et al. Reversibility of hepatic fibrosis in treated genetic hemochromatosis: a study of 36 cases. Hepatology. 2006;44(2):472–7.
Czaja AJ, Carpenter HA. Decreased fibrosis during corticosteroid therapy of autoimmune hepatitis. J Hepatol. 2004;40(4):646–52.
Kaplan MM, DeLellis RA, Wolfe HJ. Sustained biochemical and histologic remission of primary biliary cirrhosis in response to medical treatment. Ann Intern Med. 1997;126(9):682–8.
Deniz K, et al. Regression of steatohepatitis-related cirrhosis. Semin Liver Dis. 2015;35(2):199–202.
Yoon YJ, Friedman SL, Lee YA. Antifibrotic therapies: where are we now? Semin Liver Dis. 2016;36(1):87–98.
Chang TT, et al. Long-term entecavir therapy results in the reversal of fibrosis/cirrhosis and continued histological improvement in patients with chronic hepatitis B. Hepatology. 2010;52(3):886–93.
Dixon LJ, et al. Caspase-1-mediated regulation of fibrogenesis in diet-induced steatohepatitis. Lab Invest. 2012;92(5):713–23.
Pockros PJ, et al. Oral IDN-6556, an antiapoptotic caspase inhibitor, may lower aminotransferase activity in patients with chronic hepatitis C. Hepatology. 2007;46(2):324–9.
Baskin-Bey ES, et al. Cathepsin B inactivation attenuates hepatocyte apoptosis and liver damage in steatotic livers after cold ischemia-warm reperfusion injury. Am J Physiol Gastrointest Liver Physiol. 2005;288(2):G396–402.
Abu-Elheiga L, et al. Acetyl-CoA carboxylase 2−/− mutant mice are protected against fatty liver under high-fat, high-carbohydrate dietary and de novo lipogenic conditions. J Biol Chem. 2012;287(15):12578–88.
Baeck C, et al. Pharmacological inhibition of the chemokine C-C motif chemokine ligand 2 (monocyte chemoattractant protein 1) accelerates liver fibrosis regression by suppressing Ly-6C(+) macrophage infiltration in mice. Hepatology. 2014;59(3):1060–72.
Sanyal AJ, et al. Pioglitazone, vitamin E, or placebo for nonalcoholic steatohepatitis. N Engl J Med. 2010;362(18):1675–85.
Kisseleva T, et al. Myofibroblasts revert to an inactive phenotype during regression of liver fibrosis. Proc Natl Acad Sci U S A. 2012;109(24):9448–53.
Author information
Authors and Affiliations
Corresponding author
Editor information
Editors and Affiliations
Rights and permissions
Copyright information
© 2018 Springer International Publishing AG, part of Springer Nature
About this chapter
Cite this chapter
Grinspan, L.T., Verna, E.C. (2018). Chronic Liver Failure and Hepatic Cirrhosis. In: Wagener, G. (eds) Liver Anesthesiology and Critical Care Medicine. Springer, Cham. https://doi.org/10.1007/978-3-319-64298-7_2
Download citation
DOI: https://doi.org/10.1007/978-3-319-64298-7_2
Published:
Publisher Name: Springer, Cham
Print ISBN: 978-3-319-64297-0
Online ISBN: 978-3-319-64298-7
eBook Packages: MedicineMedicine (R0)